![[Valid RSS]](images/valid-rss-rogers.png "Valid RSS")
This is a valid RSS feed.
This feed is valid, but interoperability with the widest range of feed readers could be improved by implementing the following recommendations.
<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:wfw="http://wellformedweb.org/CommentAPI/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" xmlns:media="http://search.yahoo.com/mrss/" > <channel> <title>International Pharmaceutical Industry</title> <atom:link href="https://international-pharma.com/feed/" rel="self" type="application/rss+xml" /> <link>https://international-pharma.com</link> <description>Peer Reviewed, Contemporary, Authoritative</description> <lastBuildDate>Thu, 03 Jul 2025 13:10:20 +0000</lastBuildDate> <language>en-GB</language> <sy:updatePeriod> hourly </sy:updatePeriod> <sy:updateFrequency> 1 </sy:updateFrequency> <generator>https://wordpress.org/?v=6.8.1</generator> <image> <url>https://international-pharma.com/wp-content/uploads/2022/01/Favicon-IPI-150x150.png</url> <title>International Pharmaceutical Industry</title> <link>https://international-pharma.com</link> <width>32</width> <height>32</height></image> <item> <title>🔬 Join Us at Drug Discovery 2025 – A Free Festival of Life Science! YOUR LINK HERE</title> <link>https://international-pharma.com/%f0%9f%94%ac-join-us-at-drug-discovery-2025-a-free-festival-of-life-science-your-link-here/</link> <dc:creator><![CDATA[theArchitect]]></dc:creator> <pubDate>Thu, 03 Jul 2025 13:10:18 +0000</pubDate> <category><![CDATA[Industry events]]></category> <guid isPermaLink="false">https://international-pharma.com/?p=41304</guid> <description><![CDATA[We’re excited to invite our community to Drug Discovery 2025, Europe’s leading drug discovery conference, returning to Liverpool, 21–22 October 2025. Hosted by ELRIG, this free-to-attend, open-access event welcomes over 3,000 delegates, 200+ exhibitors, and 150+ talks across 14 scientific tracks—from advanced automation and chemical biology to AI‑driven therapies and sustainable drug development  Why you should attend: This is a rare opportunity to dive into […]]]></description> <content:encoded><![CDATA[<p>We’re excited to invite our community to <strong>Drug Discovery 2025</strong>, Europe’s leading drug discovery conference, returning to <strong>Liverpool</strong>, <strong>21–22 October 2025</strong>. Hosted by ELRIG, this <strong>free-to-attend</strong>, open-access event welcomes over <strong>3,000 delegates</strong>, <strong>200+ exhibitors</strong>, and <strong>150+ talks</strong> across <strong>14 scientific tracks</strong>—from advanced automation and chemical biology to AI‑driven therapies and sustainable drug development </p> <p><strong>Why you should attend:</strong></p> <ul class="wp-block-list"><li>Explore cutting-edge research with keynote speakers <strong>Prof Heather Pinkett</strong> (Northwestern University) and <strong>Dr Dafydd Owen</strong> (Pfizer) and many more</li> <li>Discover the latest in robotics, neuro‑degeneration, omics, AI, and green pharmaceutical practices</li> <li>Connect with global industry leaders in the <strong>Exhibition Hall</strong>, <strong>Breakthrough Zone</strong>, and <strong>Tech Theatre</strong></li> <li>Engage with early‑career professionals through dedicated networking events and awards</li></ul> <p>This is a rare opportunity to dive into the future of drug discovery—completely free. Whether you’re in pharma, biotech, academia, or the supplier community, this event offers invaluable insights and connections.</p> <p><strong><img src="https://s.w.org/images/core/emoji/15.1.0/72x72/1f4c5.png" alt="📅" class="wp-smiley" style="height: 1em; max-height: 1em;" /> 21–22 October 2025</strong></p> <p><strong><img src="https://s.w.org/images/core/emoji/15.1.0/72x72/1f4cd.png" alt="📍" class="wp-smiley" style="height: 1em; max-height: 1em;" /> ACC Liverpool, UK</strong></p> <p><strong><img src="https://s.w.org/images/core/emoji/15.1.0/72x72/1f39f.png" alt="🎟" class="wp-smiley" style="height: 1em; max-height: 1em;" /> Free to attend – Secure your spot now!</strong></p>]]></content:encoded> </item> <item> <title>Investing in Women: Driving Change Through Ethical Investment </title> <link>https://international-pharma.com/investing-in-women-driving-change-through-ethical-investment/</link> <dc:creator><![CDATA[theArchitect]]></dc:creator> <pubDate>Tue, 01 Jul 2025 14:41:33 +0000</pubDate> <category><![CDATA[Current Features]]></category> <category><![CDATA[Volume 17, Issue 2]]></category> <guid isPermaLink="false">https://international-pharma.com/?p=41300</guid> <description><![CDATA[Despite making up over half of the workforce in the pharmaceutical industry, women hold only about 25% of executive-level positions. In the lead-up to International Women’s Day 2025, IPI Magazine spoke with Pooja Majmudar, Investment Partner at digital health VC firm KELES, to explore how ethical investment can dismantle structural barriers and drive genuine gender […]]]></description> <content:encoded><![CDATA[<p>Despite making up over half of the workforce in the pharmaceutical industry, women hold only about 25% of executive-level positions. In the lead-up to International Women’s Day 2025, IPI Magazine spoke with Pooja Majmudar, Investment Partner at digital health VC firm KELES, to explore how ethical investment can dismantle structural barriers and drive genuine gender equality in pharma. </p> <p>Pooja’s message is clear: investors bear an ethical responsibility to champion women-led companies and diverse teams, ensuring equitable hiring, promotion, and pay policies are not just empty promises but concrete realities. </p> <p>What Metrics or Frameworks Do You Use to Assess the Impact of Ethical Investments on Gender Disparities? </p> <p>Ethical investment is not merely about avoiding harm but actively promoting positive change. It can play a crucial role in dismantling structural barriers that perpetuate gender inequality in the pharmaceutical industry, where these disparities are particularly acute, hindering progress and innovation. Any approach to tackling gender disparities must be underpinned by key metrics and robust frameworks to be effective and deliver lasting change.</p>]]></content:encoded> </item> <item> <title>All Things Sustainable Manufacturing</title> <link>https://international-pharma.com/all-things-sustainable-manufacturing/</link> <dc:creator><![CDATA[theArchitect]]></dc:creator> <pubDate>Tue, 01 Jul 2025 14:40:14 +0000</pubDate> <category><![CDATA[Current Features]]></category> <category><![CDATA[Volume 17, Issue 2]]></category> <guid isPermaLink="false">https://international-pharma.com/?p=41297</guid> <description><![CDATA[The IPI team spoke to Shivaji Jadhav from Aragen, an India-headquartered CDMO that recently received a Platinum rating from EcoVadis, placing it among the top 1% of assessed companies for sustainability practices. Shivaji discussed the practical steps CDMOs can take to advance their sustainability goals, reduce carbon emissions, and integrate responsible practices across their operations.  […]]]></description> <content:encoded><![CDATA[<p>The IPI team spoke to Shivaji Jadhav from Aragen, an India-headquartered CDMO that recently received a Platinum rating from EcoVadis, placing it among the top 1% of assessed companies for sustainability practices. Shivaji discussed the practical steps CDMOs can take to advance their sustainability goals, reduce carbon emissions, and integrate responsible practices across their operations. </p> <p>Sustainability has evolved from a compliance obligation to a strategic priority within the pharmaceutical industry. As global regulatory frameworks tighten and societal expectations shift, it has become increasingly clear that sustainable manufacturing is no longer optional but essential for long-term success. This article explores how CDMOs can embed sustainability practices into their manufacturing operations and provides a roadmap for others seeking to follow suit.</p> <p></p>]]></content:encoded> </item> <item> <title>Driving Sterile Innovation at Scale: A Conversation with PCI Pharma Services </title> <link>https://international-pharma.com/driving-sterile-innovation-at-scale-a-conversation-with-pci-pharma-services/</link> <dc:creator><![CDATA[theArchitect]]></dc:creator> <pubDate>Tue, 01 Jul 2025 14:38:27 +0000</pubDate> <category><![CDATA[Current Features]]></category> <category><![CDATA[Volume 17, Issue 2]]></category> <guid isPermaLink="false">https://international-pharma.com/?p=41293</guid> <description><![CDATA[PCI recently announced the acquisition of Ajinomoto Althea. How does this acquisition enhance PCI’s sterile fill-finish capabilities and strategy?  The acquisition of Ajinomoto Althea in San Diego, CA significantly augments PCI’s sterile fill-finish offering in North America. With proven expertise in clinical and commercial supply of sterile vial, prefilled syringe and cartridge filling, this strategic […]]]></description> <content:encoded><![CDATA[<p>PCI recently announced the acquisition of Ajinomoto Althea. How does this acquisition enhance PCI’s sterile fill-finish capabilities and strategy? </p> <p>The acquisition of Ajinomoto Althea in San Diego, CA significantly augments PCI’s sterile fill-finish offering in North America. With proven expertise in clinical and commercial supply of sterile vial, prefilled syringe and cartridge filling, this strategic addition expands our capabilities, capacities and technologies, including isolated lines, for the aseptic manufacturing of biologics, including mRNA, mAbs, LNPs, oligonucleotides, peptides, and other complex modalities.</p>]]></content:encoded> </item> <item> <title>IDMP Readiness & FAIR Data Adoption: Where Are Life Science Organisations Now? </title> <link>https://international-pharma.com/idmp-readiness-fair-data-adoption-where-are-life-science-organisations-now/</link> <dc:creator><![CDATA[theArchitect]]></dc:creator> <pubDate>Tue, 01 Jul 2025 14:36:44 +0000</pubDate> <category><![CDATA[Current Features]]></category> <category><![CDATA[Volume 17, Issue 2]]></category> <guid isPermaLink="false">https://international-pharma.com/?p=41290</guid> <description><![CDATA[Pharma companies remain at differing levels of readiness for implementing ISO IDMP product data standards, and in their maturity around adopting FAIR data principles, geared to making data more Findable, Accessible, Interoperable, and Reusable. Here, MAIN5’s Michiel Stam unpacks the findings of new research which benchmarks the industry’s progress, as well as plans to adopt […]]]></description> <content:encoded><![CDATA[<p>Pharma companies remain at differing levels of readiness for implementing ISO IDMP product data standards, and in their maturity around adopting FAIR data principles, geared to making data more Findable, Accessible, Interoperable, and Reusable. Here, MAIN5’s Michiel Stam unpacks the findings of new research which benchmarks the industry’s progress, as well as plans to adopt Pistoia Alliance’s IDMP-Ontology to optimise standardised data use. </p> <p>Although ISO IDMP standards, designed to harmonise the way the life sciences industry records and manages data about its products, have been more than a decade in the making, companies’ state of readiness to implement and harness IDMP still varies considerably.</p>]]></content:encoded> </item> <item> <title>Understanding the UK’s International Recognition Procedure </title> <link>https://international-pharma.com/understanding-the-uks-international-recognition-procedure/</link> <dc:creator><![CDATA[theArchitect]]></dc:creator> <pubDate>Tue, 01 Jul 2025 14:35:33 +0000</pubDate> <category><![CDATA[Current Features]]></category> <category><![CDATA[Volume 17, Issue 2]]></category> <guid isPermaLink="false">https://international-pharma.com/?p=41287</guid> <description><![CDATA[Since the United Kingdom’s exit from the European Union in 2020, there have been numerous changes in the procedures implemented to ensure that there is access to medicines for UK patients. One area of interest and a growing topic of discussion in the pharmaceutical industry is the International Recognition Procedure (IRP) which was introduced by […]]]></description> <content:encoded><![CDATA[<p>Since the United Kingdom’s exit from the European Union in 2020, there have been numerous changes in the procedures implemented to ensure that there is access to medicines for UK patients. One area of interest and a growing topic of discussion in the pharmaceutical industry is the International Recognition Procedure (IRP) which was introduced by the Medicines and Healthcare products Regulatory Agency (MHRA) on 1 January 2024, replacing and expanding on the EC Decision Reliance Procedure (ECDRP). </p> <p>The introduction of the IRP has brought opportunities for faster market access for manufacturers by enabling the MHRA to conduct more targeted assessments by taking into account the expertise and decision-making of trusted regulatory partners.</p> <p></p>]]></content:encoded> </item> <item> <title>Welcome Relief for PV Scientists: A Fresh Take on Local Literature Monitoring </title> <link>https://international-pharma.com/welcome-relief-for-pv-scientists-a-fresh-take-on-local-literature-monitoring/</link> <dc:creator><![CDATA[theArchitect]]></dc:creator> <pubDate>Tue, 01 Jul 2025 14:32:56 +0000</pubDate> <category><![CDATA[Current Features]]></category> <category><![CDATA[Volume 17, Issue 2]]></category> <guid isPermaLink="false">https://international-pharma.com/?p=41284</guid> <description><![CDATA[Pharmacovigilance is by its nature a detail-driven undertaking, and within it monitoring medical literature for safety signals is notoriously labour-intensive. Nowhere more so than at a local level, where barriers including language, format, subscriptions and paywalls can hamper access to what may be modest yet critical findings. Intelligent automation potentially easing this essential work comes […]]]></description> <content:encoded><![CDATA[<p>Pharmacovigilance is by its nature a detail-driven undertaking, and within it monitoring medical literature for safety signals is notoriously labour-intensive. Nowhere more so than at a local level, where barriers including language, format, subscriptions and paywalls can hamper access to what may be modest yet critical findings. Intelligent automation potentially easing this essential work comes as a huge relief, as volumes of content – and costs – continue to multiply, says Biologit’s Nicole Baker. </p> <p>The monitoring and prevention of adverse drug events, the essence of pharmacovigilance, or PV, is vital to patient safety across a medication’s lifecycle. Whatever pains have been taken to mitigate risk during product development and clinical trials, adverse events from medications are relatively common. The earlier drug companies can detect problems, the sooner they can take appropriate action to maintain and heighten patient safety. </p> <p>Medical literature monitoring – the systematic review of published reports of adverse events in published materials – is a core activity within PV. At a worldwide level, the practice is relatively straightforward, involving systematic scanning of highprofile, indexed journals via large databases.</p>]]></content:encoded> </item> <item> <title>Developing Approaches for mRNA Vaccines in Oncology</title> <link>https://international-pharma.com/developing-approaches-for-mrna-vaccines-in-oncology/</link> <dc:creator><![CDATA[theArchitect]]></dc:creator> <pubDate>Tue, 01 Jul 2025 14:30:09 +0000</pubDate> <category><![CDATA[Current Features]]></category> <category><![CDATA[Volume 17, Issue 2]]></category> <guid isPermaLink="false">https://international-pharma.com/?p=41281</guid> <description><![CDATA[A key challenge in developing therapeutic vaccines against cancer is getting the correct vaccine target delivered to the correct immune cells in the correct cellular context. A variety of mRNA-based approaches are showing great promise in achieving these goals. mRNA vaccines can be integrated into flexible and modular immunotherapeutic strategies designed to address the specific […]]]></description> <content:encoded><![CDATA[<p>A key challenge in developing therapeutic vaccines against cancer is getting the correct vaccine target delivered to the correct immune cells in the correct cellular context. A variety of mRNA-based approaches are showing great promise in achieving these goals. mRNA vaccines can be integrated into flexible and modular immunotherapeutic strategies designed to address the specific needs of persons with cancer. Flexible approaches make mRNA vaccines ideal for the development of personalised precision approaches to drive immune responses to neoantigens from the patient’s own tumour.</p> <p>Every form of cancer originates from a healthy cell. The developing immune system is educated to tolerate protein antigens expressed by healthy cells as “self” antigens. Cancer occurs when healthy cells start to break free from multiple layers of genetic mechanisms that restrict and suppress cellular replication, leading to uncontrolled and inappropriate proliferation. As a tumour develops, the malignant cells often begin to express proteins that serve as potential anti-tumour immune targets, or Tumour Associated Antigens (TAAs). </p> <p>As part of this process, malignant cells generally lose the quality control mechanisms that ensure high-fidelity DNA replication, such that growing tumours can express increasing quantities of proteins representing genetic mutations. These mutations often encode peptide sequences or “neoantigens” that are different enough from the self-sequence that the immune system may recognise them as “non-self.” Aside from neoantigens, TAAs may include unmutated self-proteins expressed in an inappropriate context.</p>]]></content:encoded> </item> <item> <title>Life Cycle Assessment: A data-driven Approach to Drug Delivery Device Sustainability</title> <link>https://international-pharma.com/life-cycle-assessment-a-data-driven-approach-to-drug-delivery-device-sustainability/</link> <dc:creator><![CDATA[theArchitect]]></dc:creator> <pubDate>Tue, 01 Jul 2025 14:28:18 +0000</pubDate> <category><![CDATA[Current Features]]></category> <category><![CDATA[Uncategorised]]></category> <category><![CDATA[Volume 17, Issue 2]]></category> <guid isPermaLink="false">https://international-pharma.com/?p=41277</guid> <description><![CDATA[The drug delivery device industry faces a number of significant challenges with regard to sustainability, from reliance on single-use plastics to resource-intensive manufacturing processes. In the waste hierarchy, where waste prevention is most favourable and disposal the last resort, the industry has some way to go before ‘prevention’ – i.e., using fewer resources to make […]]]></description> <content:encoded><![CDATA[<p>The drug delivery device industry faces a number of significant challenges with regard to sustainability, from reliance on single-use plastics to resource-intensive manufacturing processes. In the waste hierarchy, where waste prevention is most favourable and disposal the last resort, the industry has some way to go before ‘prevention’ – i.e., using fewer resources to make a product, and enabling reuse – is the default. Yet this route has significant benefits for the environment. </p> <p>For instance, according to an Owen Mumford analysis, one single-use disposable auto-injector has a carbon footprint of approximately 400 g CO₂e. It is possible, by modifying a number of product characteristics, to potentially reduce this footprint to only 19 g CO₂e through a reusable and remanufacturable device. This solution also aligns with the Centre for Sustainable Healthcare’s guidance for the sector, which advocates for lean service delivery to minimise wasteful activities and the prioritisation of low-carbon treatments and technologies. </p> <p>At the same time, pharmaceutical companies – close partners with device manufacturers – face mounting pressure to prioritise sustainability, from regulatory bodies, consumers and investors alike. And they are committing to ambitious targets in this area: nineteen of the twenty biggest pharmaceutical companies have committed to reducing greenhouse gas (GHG) emissions, ten to carbon neutrality and eight to net zero emissions between 2025 and 2050.</p>]]></content:encoded> </item> <item> <title>Putting the Patient First: Optimising Injectable Drug Development for Clinical Success</title> <link>https://international-pharma.com/putting-the-patient-first-optimising-injectable-drug-development-for-clinical-success/</link> <dc:creator><![CDATA[theArchitect]]></dc:creator> <pubDate>Tue, 01 Jul 2025 14:25:56 +0000</pubDate> <category><![CDATA[Current Features]]></category> <category><![CDATA[Volume 17, Issue 2]]></category> <guid isPermaLink="false">https://international-pharma.com/?p=41271</guid> <description><![CDATA[As injectable drugs continue to expand across therapeutic areas, designing patient-centric clinical trials is critical for success. This article explores the intersection of formulation science and device design – highlighting how formulation development and advanced autoinjector platforms like Jabil’s Qfinity+™ autoinjector can improve patient experience, adherence, and outcomes. Key formulation and usability factors such as […]]]></description> <content:encoded><![CDATA[<p>As injectable drugs continue to expand across therapeutic areas, designing patient-centric clinical trials is critical for success. This article explores the intersection of formulation science and device design – highlighting how formulation development and advanced autoinjector platforms like Jabil’s Qfinity+<img src="https://s.w.org/images/core/emoji/15.1.0/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> autoinjector can improve patient experience, adherence, and outcomes. Key formulation and usability factors such as excipient selection, viscosity, administration force, and usability testing are discussed in the context of clinical trial design and patient engagement. </p> <p>Injectable drug development is experiencing a profound shift toward patient-centricity, reshaping how therapies are formulated, delivered, and regulated. One of the most notable trends is the rise of self-administered injectable therapies. Driven by the growth of biologics and the increasing need for chronic disease management outside traditional healthcare settings, patients are seeking treatments that fit into their daily lives. Pharmaceutical companies are responding with safety syringe devices, autoinjectors, which commonly comprise a pre-filled syringe, and wearable devices designed to simplify administration and improve adherence.</p>]]></content:encoded> </item> </channel></rss> If you would like to create a banner that links to this page (i.e. this validation result), do the following:
Download the "valid RSS" banner.
Upload the image to your own server. (This step is important. Please do not link directly to the image on this server.)
Add this HTML to your page (change the image src attribute if necessary):
If you would like to create a text link instead, here is the URL you can use:
http://www.feedvalidator.org/check.cgi?url=https%3A//international-pharma.com/feed/
